RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 48.4%

Neg 0% Neu 48.4% Pos 0%

RBC Capital analyst Brian Abrahams reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Sector Perform and maintains $6 price target.